Abstract
Introduction: multiple sclerosis is the most disabling chronic disease affecting the central nervous system in young adults and characterized by the accumulation of physical disability varying degrees.
Objectives: determine the progression of physical disability in patients diagnosed with multiple sclerosis treated with interferon beta-1b. To establish adherence to treatment and safety.
Materials and Methods: observational study carried out at 9 neurological centers from the Atlantic Coast of Colombia with patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) or clinically isolated syndrome (CIS) treated with interferon beta-1b.Physical disability was measured with 5 clinical evaluations with Kurtzke´s Expanded Disability Status Scale (EDSS).
Results: 83 patients, mean age of 43.4 years (61.5% women). 71.1% of patients had RRMS, 20.1% SPMS and 4.8% CIS. Mean EDSS score remained under 4 (initial 3.7, final 3.5, p=0.712). No differences were found between initial scores and scores after 24 months of observation in patients with RRMS (mean, 3.7 vs 3.4, p=0.424) or SPMS group (mean, 4.0 vs 4.2, p=0.660).17 treatment interruptions occurred. 8.4% of patients experienced adverse events, 4 classified as serious. 2 fatal cases occurred.
Conclusion: the functional status of patients with multiple sclerosis treated with interferon beta-1b remained stable without significant changes present in patients with RRMS and SPMS.
References
Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62: 601-606.
Cristiano E, Patruccco L, Rojas I. A systematic review of the epidemiology of multiple sclerosis in South America. Eur J Neurol 2008; 15: 1273-1278.
Melcon MO, Melcon CM, Bartoloni L, et al. Towards establishing MS prevalence in Latin America and the Caribbean. MultScler 2012; publicado en línea el 4 de abril de 2012.DOI: 10.1177/1352458512441985. Consultado el 28 de mayo de 2012.
Luetic G. MS in Latin America.Int MS J 2008; 15: 6-11.
Sánchez JL, Aguirre C, Arcos-Burgos OM, et al. Prevalence of multiple sclerosis in Colombia. Revista de Neurología 2000; 31: 1101-1103.
Toro J, Sarmiento OL, Díaz del Castillo A, et al. Prevalence of multiplesclerosis in Bogota, Colombia. Neuroepidemiology 2007; 28: 33-38.
Risco J, Maldonado H, Luna L, et al. Latitudinal prevalence gradient of multiple sclerosis in Latin America. MultScler 2011; 17 (9): 1055-1059.
Confavreux Ch, Vukusik S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
Cohen JA, Reingold SC, PolmanCh H, et al. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012; 11: 467-76.
Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51-59.
Rudick R, Antel J, Confavreux Ch, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-382.
Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929.
Scalfari A, Neuhaus A, Daumer M, et al. Age and disability accumulation in multiple sclerosis. Neurology 2011; 77: 1246-1252.
TREMLETT H, PATY D, DEVONSHIRE V. Disability progression in multiple sclerosis is lower than previously reported. Neurology 2006; 66: 172-177.
MARRIE RA, CUTTER G, TYRY T, ET AL. Does multiple sclerosis-associated disability differ between races? Neurology 2006; 66: 1235-1240.
RUDICK RA, STUART WH, CALABRESI PA, ET AL. Natalizumab plus interferon beta-1 a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
GIOVANNONI G, SOUTHAM E, WAUBANT E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. MultScler 2011; publicado en línea el 16 de enero de 2012.DOI: 10.1177/1352458511433302. Consultado el 28 de mayo de 2012
RICE GP, INCORVAIA B, MUNARI L, ET AL. Interferon in relapsing-remitting multiple sclerosis. Cochrane database Syst Rev 2001; CD 002002.
FILIPPINI G, MUNARI L, INCORVAIA B, ET AL. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361: 545-552.
SCOLDING NJ. Long-term beta interferon in MS: safe, but what effect on disability? J NeurolNeurosurg Psychiatry 2010; 81: 825-826.
COMI G, FILIPPI M, BARKHOFF F, ET AL. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001; 357: 1576-82.
KAPPOS L, FREEDMANN MS, POLMAN, ET AL, FOR THE BENEFIT STUDY GROUP. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389-97.
COMI G, MARTINELLI V, RODEGHER M, ET AL, FOR THE PRECISE STUDY GROUP. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo- controlled trial. Lancet 2009; 374: 1503-11.
COMI G, DE STEFANO N, FREEDMAN MS, ET AL. Comparison of two dosing frequencies of subcutaneous interferon beta 1-a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33-41.
KAPPOS L, FREEDMAN MS, POLMANCH, ET AL, FOR THE BENEFIT STUDY GROUP. Long-term effect of early treatment with interferon beta 1-b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-97.
KINKEL RP, KOLLMANC, O´CONNOR P, ET AL. IM interferon beta-1 a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66: 678-84.
EBERS GC, HEIGENHAUSER L, DAUMER M, ET AL. Disability as an outcome in MS clinical trials. Neurology 2008; 71: 624-631.
SHIRANI A, ZHAO Y, EHSANUL KARIM M, ET AL. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308(3):247-256.
POLMAN CH, RUDICK RA. The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability. Neurology 2010; 74(Suppl 3): S8-S15.
CARRÁ A, MACÍAS-ISLAS MA, GABBAI AA, Y COLS. Optimización de resultados en la esclerosis múltiple: consenso para el diagnóstico y el tratamiento de la esclerosis múltiple en Latinoamérica. TherAdvNeurolDisord 2011; 4(6).349-360.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.